Salix Pharmaceuticals (SLXP) +8.4% premarket after saying that an FDA advisory panel supports...

|About: Salix Pharmaceuticals, Ltd. (SLXP)|By:, SA News Editor

Salix Pharmaceuticals (SLXP) +8.4% premarket after saying that an FDA advisory panel supports its proposed trial to test repeat treatment cycles of its Xifaxan tablets for irritable bowel syndrome. (earlier)